This renewal proposal seeks continued funding for the Training program in Translational Cardiovascular Research and Entrepreneurship (CVRE) at the University of Michigan. Cardiovascular disease is the leading cause of death worldwide. The mission of this program is to train the next generation of PhD scientists seeking careers in cardiovascular research in the ethical development and application of research results from the laboratory to the bedside, with the ultimate goal of improving therapy for patients. The proposed training program is intentionally designed to address the gap in training of young basic scientists and pre-doctoral students in key areas of translational cardiovascular research such as preclinical research design, drug discovery, device/therapy development, optimization and testing, research entrepreneurship, and regulatory compliance. The interdisciplinary and internationally recognized faculty of this program provides an outstanding training environment that includes state of the art facilities and techniques spanning genetic, molecular, cellular, systems, engineering and clinical investigation of both vascular and cardiac diseases. By capitalizing on the existing strengths of our faculty in basic, preclinical, and translational cardiovascular research, and unique academic resources at the University of Michigan, we will train students not only in state of the art biomedical research, but also in applying systems biology for preclinical testing, navigating regulatory compliance, and the process and challenges of research entrepreneurship. Therefore, this program offers students a unique comprehensive and immersive educational experience in translational research training. The added benefit is that the program will also prepare students for the diversity of scientific careers available to and often pursued by young scientists including academic research, start-up companies, biotechnology and large pharmaceutical and device companies. The Translational CVRE program will attract trainees at the PhD Candidate level from laboratories across the Frankel Cardiovascular Center faculty membership, from exceptionally strong graduate programs in the medical school wide Program in Biomedical Sciences, and the College of Engineering and School of Pharmacy. Funds are requested for 5 trainee slots per year, and students may be reappointed for a second year by competitive renewal. The key program features are 1) strong, fundamental basic research training on translationally relevant research topics under the NHLBI mission 2) training in preclinical research design and phenotypic testing 3) didactic and experiential learning on research entrepreneurship along with career path relevant skills development. By placing students at the interface between basic cardiovascular research, biomedical engineering, and cardiovascular medicine, we hope to better prepare the next generation of PhD scientists to be leaders at taking basic research discoveries and being capable of directing their path to the clinic.
Cardiovascular disease is the leading cause of death worldwide. The Translational Cardiovascular Research and Entrepreneurship Training Program is focused on training the next generation of PhD scientists to be capable of both making discoveries in the molecular mechanisms of cardiovascular disease and leading research programs to guide the translation of those discoveries into effective therapies that can be applied in clinical medicine. This training program will therefore contribute to accelerating the translation of laboratory discoveries into clinical therapies that directly impact our ability to improve treatment of human cardiovascular disease.
|Crouch, A Colleen; Manders, Adam B; Cao, Amos A et al. (2018) Cross-sectional area of the murine aorta linearly increases with increasing core body temperature. Int J Hyperthermia 34:1121-1133|
|Li, Dan; Fawaz, Maria V; Morin, Emily E et al. (2018) Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics. Mol Pharm 15:83-96|
|Yu, Minzhi; Benjamin, Mason M; Srinivasan, Santhanakrishnan et al. (2018) Battle of GLP-1 delivery technologies. Adv Drug Deliv Rev 130:113-130|
|Kong, Yen P; Rioja, Ana Y; Xue, Xufeng et al. (2018) A systems mechanobiology model to predict cardiac reprogramming outcomes on different biomaterials. Biomaterials 181:280-292|
|Morin, Emily E; Li, Xiang-An; Schwendeman, Anna (2018) HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic. Front Endocrinol (Lausanne) 9:715|
|Guo, Yanhong; Yuan, Wenmin; Yu, Bilian et al. (2018) Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression. EBioMedicine 28:225-233|
|Rioja, Ana Y; Daley, Ethan L H; Habif, Julia C et al. (2017) Distributed vasculogenesis from modular agarose-hydroxyapatite-fibrinogen microbeads. Acta Biomater 55:144-152|
|Kuruvilla, Sibu P; Tiruchinapally, Gopinath; Crouch, A Colleen et al. (2017) Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model. PLoS One 12:e0181944|
|Tang, Jie; Li, Dan; Drake, Lindsey et al. (2017) Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization. J Lipid Res 58:124-136|
|Fromen, Catherine A; Kelley, William J; Fish, Margaret B et al. (2017) Neutrophil-Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation. ACS Nano 11:10797-10807|
Showing the most recent 10 out of 18 publications